Tenaya Therapeutics. has filed a patent for methods of treating metabolic disease and heart failure with preserved ejection fraction using HDAC6 inhibitors. The patent includes various HDAC6 inhibitors for oral administration to human patients. Claim 1-71 has been canceled. GlobalData’s report on Tenaya Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Tenaya Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Tenaya Therapeutics, Recombinant AAV gene therapy was a key innovation area identified from patents. Tenaya Therapeutics's grant share as of January 2024 was 8%. Grant share is based on the ratio of number of grants to total number of patents.

Treating metabolic disease and heart failure with hdac6 inhibitor

Source: United States Patent and Trademark Office (USPTO). Credit: Tenaya Therapeutics Inc

The patent application (Publication Number: US20230381148A1) describes a method for treating or preventing metabolic diseases in humans by administering an HDAC6 inhibitor. The method involves using a specific compound according to Formula (I) as the HDAC6 inhibitor. The metabolic diseases that can be targeted include diabetes, pre-diabetes, diabetic cardiomyopathy, metabolic syndrome, hypertension, hypertriglyceridemia, dyslipidemia, and obesity. The method aims to improve glucose tolerance, insulin resistance, and reduce glucose levels in patients with these conditions.

Furthermore, the patent application also covers a method for treating or preventing heart failure with preserved ejection fraction (HFpEF) by administering an HDAC6 inhibitor to the subject. The compound used as the HDAC6 inhibitor in this case is also according to Formula (I). This method could potentially offer a new approach to managing HFpEF, a condition characterized by heart failure despite the heart's normal pumping function. By targeting HDAC6 with the specific compound outlined in the patent, there is a possibility of improving outcomes for individuals with HFpEF.

To know more about GlobalData’s detailed insights on Tenaya Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies